Tanya Lewis, assistant editor at Scientific American, discusses the new tax the Trump administration recently placed on imported solar panels. She weighs in on what the decision means for the U.S. economy and for the consumer. Some are deriding the tariff as a "job killer" and others are saying the move, meant to protect U.S. manufacturers, may not be as bad as some think. Lewis talks about Trump's first year in office and the impact his administration has had on science. Since taking office, Trump has pulled out of the Paris Climate Agreement and scaled back national monuments.

Share:
More In Business
Hard pass, Cold brew, Dad bod: Merriam-Webster adds 5,000 new words
Merriam-Webster has fully revised its popular “Collegiate” dictionary with over 5,000 new words. They include “petrichor,” “dumbphone” and “ghost kitchen.” Also “cold brew,” “rizz,” “dad bod,” “hard pass,” “cancel culture” and more.
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More